Financial Performance - The company's operating revenue for Q3 2022 was ¥1,012,162,607.26, representing a year-on-year increase of 1.88%[4] - The net profit attributable to shareholders for Q3 2022 was ¥172,919,418.17, with a year-on-year increase of 2.51%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥165,844,941.69, reflecting a year-on-year increase of 0.89%[4] - Total operating revenue for the first three quarters of 2022 reached ¥2,988,666,620.15, an increase of 6.5% compared to ¥2,805,526,162.50 in the same period of 2021[16] - Net profit for the third quarter of 2022 was ¥494,800,984.91, compared to ¥469,683,871.58 in the same quarter of 2021, representing a growth of 5.3%[17] - The company reported a total profit of ¥576,765,745.43 for the third quarter of 2022, up from ¥551,728,276.55 in the same quarter of 2021, reflecting a growth of 4.5%[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,728,673,220.10, an increase of 4.98% compared to the end of the previous year[5] - The equity attributable to shareholders at the end of the reporting period was ¥4,994,661,126.66, up 6.95% from the previous year[5] - Total assets as of September 30, 2022, amounted to ¥6,728,673,220.10, an increase from ¥6,409,715,397.53 as of December 31, 2021[14] - Total liabilities amounted to ¥1,734,012,093.44, slightly down from ¥1,739,411,613.91 in the previous year[15] - The company’s total liabilities decreased to ¥1,673,286,549.71, down from ¥1,679,446,222.37, indicating a slight improvement in financial health[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥199,142,085.64, showing a decline of 50.42% compared to the previous year[5] - In the first three quarters of 2022, the cash inflow from operating activities amounted to CNY 2,700,512,150.02, an increase of 11.7% compared to CNY 2,416,537,854.15 in the same period of 2021[19] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 199,142,085.64, a decrease of 50.5% from CNY 401,691,941.00 in the previous year[21] - The cash outflow from operating activities totaled CNY 2,501,370,064.38, up 24.1% from CNY 2,014,845,913.15 in the same period of 2021[21] - The cash inflow from investment activities was CNY 658,903,823.63, compared to CNY 619,536,357.70 in the previous year, reflecting a growth of 6.3%[21] - The net cash flow from investment activities was -CNY 327,243,646.44, an improvement from -CNY 647,470,907.13 in the same period of 2021[21] Inventory and Receivables - The company's inventory increased by 36.63% year-to-date, primarily due to rising raw material costs and increased production capacity[7] - Accounts receivable increased to ¥842,522,069.40 from ¥764,358,649.73, reflecting a growth of about 10.2%[13] - Inventory rose significantly to ¥1,199,218,984.19, compared to ¥877,737,495.86, marking an increase of approximately 36.6%[13] Earnings and Expenses - The basic earnings per share for Q3 2022 was ¥0.2906, a year-on-year increase of 2.50%[5] - Earnings per share for the third quarter of 2022 were ¥0.8316, an increase from ¥0.7894 in the same quarter of 2021[18] - Research and development expenses for the third quarter of 2022 were ¥104,317,377.43, compared to ¥102,030,196.60 in the same quarter of 2021, showing an increase of 2.2%[17] Cash and Equivalents - Cash and cash equivalents decreased to ¥611,062,771.84 from ¥885,044,113.42 year-over-year, representing a decline of approximately 30.8%[13] - The cash and cash equivalents at the end of the period were CNY 426,933,280.24, down from CNY 607,130,365.18 at the end of the same period in 2021[21]
山东药玻(600529) - 2022 Q3 - 季度财报